Medication info
Cretcandee Tablet 10/16 mg

Cretcandee Tablet 10/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Hankook Hyutec Pharmaceutical Co., Ltd.
Appearance
Yellow circular film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202008725 · Approved 2020.12.11 · Insurance code 649105110

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil taken orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or longer, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in adolescents and children 18 years of age or younger have not been established. The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hankook Hyutec Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who require co-administration of two drugs, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is mainly used for patients with essential hypertension or heart failure, especially in cases of left ventricular dysfunction, when used as an add-on therapy to ACE inhibitors or when tolerance is poor. Rosuvastatin is administered as an adjunct when dietary therapy and exercise do not control hypercholesterolemia and combined hyperlipidemia, helping to slow the progression of atherosclerosis and reduce the risk of cardiovascular disease. It is particularly effective in reducing the risk of stroke and myocardial infarction in middle-aged patients with high-sensitive C-reactive protein levels. This medication improves cardiovascular health by managing both hypertension and hyperlipidemia.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil taken orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or longer, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in adolescents and children 18 years of age or younger have not been established. The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can pose serious risks to the fetus during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It should not be used by patients with hypersensitivity to this medication, severe liver function impairment, pregnant or breastfeeding women, or patients with severe renal failure. Elderly patients, patients with slightly impaired liver function, or patients with hyperkalemia should use this medication cautiously and undergo regular blood tests and kidney function tests while on the medication. If symptoms such as myalgia, muscle weakness, or cramps occur, consult a physician immediately; if these symptoms are severe or blood tests show elevated markers of muscle damage, the medication should be discontinued. This medication may increase liver enzyme levels, so liver function tests should be performed regularly, and if abnormalities are detected, the medication should be discontinued. Interactions may occur when taken with other antihypertensives, diuretics, potassium supplements, certain antibiotics, antifungals, etc., so inform your physician or pharmacist of any other medications being taken. Reduce alcohol consumption while taking this medication, and be cautious of dizziness due to sudden drops in blood pressure, especially when driving or operating machinery. Pregnant or breastfeeding women should not use this medication, and those planning to become pregnant should use appropriate contraception. In cases of overdose, appropriate treatment is needed based on symptoms, and there is no specific antidote; immediate hospital visit is required. The safety and efficacy in children have not been established, so it is not recommended. Store this medication out of reach of children and keep it in the original container to prevent misuse.

Side effects

headache, nasopharyngitis, local infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, position-related dizziness, milia, periodontitis, inflammation, foreign body sensation, cataract, musculoskeletal pain, neck pain, increased blood glucose, decreased serum sodium, tooth extraction, chest discomfort, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, thrombocytopenia, increased serum creatinine, acute renal failure, oliguria, myalgia, increased CK, increased ALT, increased AST, weakness, joint pain, constipation, loss of appetite, abdominal distension, abnormal liver function tests, sensory disturbances, chest discomfort, cough, myopathy, rhabdomyolysis, hematuria, rash, urticaria, angioedema, increased blood pressure, hyperkalemia, hyponatremia, hypotension, shock, loss of consciousness, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, dizziness, position-related dizziness, adrenal insufficiency, paralysis, hypertonia, facial flushing, facial edema, thirst, sleep disorder, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, dysgeusia, erectile dysfunction, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, hepatitis, jaundice, hepatic dysfunction, rash, urticaria, itching, angioedema, myalgia, weakness, elevated creatine kinase, elevated myoglobin in serum and urine, rhabdomyolysis, joint pain, myalgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, hypotension, dizziness, weakness, headache, chest pain, myalgia, increased CK, increased ALT, increased AST, constipation, loss of appetite, abdominal distension, abnormal liver function tests, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, rash, urticaria, itching, angioedema, myalgia, myopathy, rhabdomyolysis, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, severe myasthenia, ophthalmoplegia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, ideally at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

Yellow circular film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.